| Ytd | 0.26% | |
| 1y | 93.03% |
| Open | 34.33 | Prev Close | 33.89 | Low | 34.06 | High | 35.40 | Mkt Cap | 4.11B |
| Vol | 867.67K | Avg Vol | 1.29M | EPS | -1.78 | P/E | N/A | Forward P/E | -27.63 |
| Beta | 0.08 | Short Ratio | 7.09 | Inst. Own | 106.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 32.68 | 200-d Avg | 33.56 | 1yr Est | 49.46 |
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf